Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Biol Ther. 2009 May 18;8(10):939–950. doi: 10.4161/cbt.8.10.8213

Figure 4. Co-treatment with decitabine and panobinostat enhances DNMT1 depletion and JunB induction.

Figure 4

A. K562 cells were treated with the indicated concentrations of DAC and panobinostat for 24 hours. Immunoblot analysis was performed for DNMT1, EZH2, hsp70, and JunB on the total cell lysates. The expression levels of β-actin in the cell lysates served as the loading control. B. Primary acute leukemia cells were treated with the indicated concentrations of DAC and panobinostat for 24 hours. Immunoblot analysis was performed for DNMT1, EZH2 and JunB on the total cell lysates. The levels of β-actin in the cell lysates served as the loading control. C. K562 cells were treated with 20 nmol/L of panobinostat and 1 μmol/L of decitabine in the manner indicated for 24 hours. Following this, total RNA were isolated and qPCR analysis was performed for exon 1 of JunB mRNA. Expression of JunB mRNA was normalized against GAPDH. Alternatively, Western blot analysis was performed for JunB on the total cell lysates. The expression levels of β-actin in the lysates served as the loading control.